Dianthus Therapeutics, Inc.
DNTH
Pozycja w akcjach
#3909
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Cena akcji
$74.81
Kapitalizacja rynkowa
$4.18B
Zmiana (1 dzień)
3.77%
Zmiana (1 rok)
109.85%
Kraj
US
Handel Dianthus Therapeutics, Inc. (DNTH)
Kategoria
Healthcare
Wskaźnik P/S dla Dianthus Therapeutics, Inc. (DNTH)
Wskaźnik P/S na dzień October 2026 TTM: 2.20K
Według najnowszych raportów finansowych i ceny akcji Dianthus Therapeutics, Inc., obecny wskaźnik P/S (TTM) wynosi 2.20K. Na koniec 2023 wynosił 18.97.
Historia wskaźnika P/S dla Dianthus Therapeutics, Inc. od 2016 do 2026
Wskaźnik P/S na koniec każdego roku
| Rok | Wskaźnik P/S | Zmień |
|---|---|---|
| 2026 (TTM) | 2.20K | 1,785.51% |
| 2024 | 116.48 | 514.17% |
| 2023 | 18.97 | 413.89% |
| 2022 | 3.69 | -97.76% |
| 2021 | 164.92 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
Wskaźnik P/S dla podobnych firm lub konkurentów
| Firma | Wskaźnik P/S | Różnica wskaźnika P/S | Kraj |
|---|---|---|---|
| 10.02 | -99.54% |
US
|
|
| 40.55 | -98.15% |
US
|
|
| 3.96 | -99.82% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -99.54% |
NL
|
